Title

Codagenix raises $20 million for a new flu vaccine and other therapies

Codagenix, a company developing vaccines and viral therapies for illnesses ranging from the flu and respiratory viruses to dengue fever, has raised $20 million in a new round of financing.

Codagenix said it will use the new financing to bring its RSV and flu vaccines through Phase 1 trials and move its oncology program for a breast cancer treatment into Phase 1 clinical trials.

Full Article